Adult Immunization

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.

IDWeek 2024: Black individuals were less likely to be vaccinated against all 3 respiratory viruses than White individuals, according to new research.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.

Your daily dose of the clinical news you may have missed.

New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.

Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

The new data amend that from prelicensure trials, which did not include fair representation of older adults and others more vulnerable to severe RSV disease.

The Bridge Access Program allowed Americans who are uninsured or underinsured to receive COVID-19 vaccination at not cost and was ended abruptly last month.

The “Do It For You & Them” campaign focuses on the impact that virus has on day-to-day lives.

PfizerForAll offers telehealth and prescription services, vaccination scheduling and savings programs, and is partnering with recognized companies such as InstaCart.

Topics include declining vaccine coverage among kindergarten-aged children and key changes in recommendations for adult vaccination.

Now that the WHO has declared a second mpox global emergency, you may want to brush up on knowledge of the disease and the 2024 outbreak.

Do you know the ACIP-preferred influenza vaccine for adults aged ≥65 yrs? The cut-off age for HPV vaccination? The time between the 2-dose mpox series? More, here.

The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.